KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Investing Activities: 2011-2025

Historic Cash from Investing Activities for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to $232.4 million.

  • Sarepta Therapeutics' Cash from Investing Activities rose 280.40% to $232.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $737.6 million, marking a year-over-year increase of 1111.52%. This contributed to the annual value of $755.6 million for FY2024, which is 555.70% up from last year.
  • Sarepta Therapeutics' Cash from Investing Activities amounted to $232.4 million in Q3 2025, which was up 621.49% from $32.2 million recorded in Q2 2025.
  • Sarepta Therapeutics' 5-year Cash from Investing Activities high stood at $764.1 million for Q4 2024, and its period low was -$785.8 million during Q1 2022.
  • For the 3-year period, Sarepta Therapeutics' Cash from Investing Activities averaged around $51.2 million, with its median value being $12.5 million (2023).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 1,201.37% in 2023, then surged by 1,651.49% in 2024.
  • Quarterly analysis of 5 years shows Sarepta Therapeutics' Cash from Investing Activities stood at -$2.6 million in 2021, then skyrocketed by 480.13% to $9.8 million in 2022, then crashed by 756.98% to -$64.4 million in 2023, then skyrocketed by 1,287.29% to $764.1 million in 2024, then spiked by 280.40% to $232.4 million in 2025.
  • Its last three reported values are $232.4 million in Q3 2025, $32.2 million for Q2 2025, and -$291.2 million during Q1 2025.